Open AccessLong-Term Hepatitis B Virus Surface Antigen Decay in HIV-1/Hepatitis B Virus-Coinfected Adults Initiating a Tenofovir-Containing Regimen
Author(s) -
Édouard Tuaillon,
Carlos Lozano,
Nils Kuster,
A. Poinso,
Dramane Kania,
Nicolas Nagot,
A.-M. Mondain,
GeorgesPhilippe Pageaux,
J Ducos,
Philippe Van de Perre,
JeanMarc Reynes
Publication year - 2012
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00971-12
Subject(s) - hbsag , hepatitis b virus , medicine , regimen , virology , tenofovir , hepatitis b , virus , human immunodeficiency virus (hiv) , confidence interval , hepatitis c virus , gastroenterology , immunology
Hepatitis B virus (HBV) surface antigen (HBsAg) decay was explored in HIV-1- and HBV-coinfected patients beginning antiretroviral (ARV) therapy containing tenofovir disoproxil fumarate (TDF). The mean HBsAg decay was 0.38 log10 IU/ml/year (95% confidence interval [CI], 0.71 to 0.05) in 18 patients with sustained plasma HIV-1 RNA suppression and 0.15 log10 IU/ml/year (0.21 to 0.09) in 12 patients experiencing HIV-1 virologic failure due to suboptimal adherence to ARV (P = 0.17). We estimated that six of these 18 patients will attain HBsAg values below 10 IU/ml after 10 years of treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom